资源描述：
《Single-agent PARP inhibitors for the treatment of patients with BRCAmutated HER2-negative metastatic breast cancer_ a systematic review and meta-analysis英文资料》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。
1、OpenaccessReviewESMOOpen:firstpublishedas10.1136/esmoopen-2018-000361on20June2018.DownloadedfromSingle-agentPARPinhibitorsforthetreatmentofpatientswithBRCA-mutatedHER2-negativemetastaticbreastcancer:asystematicreviewandmeta-analysis1,2332FrancescaPoggio,MarcoBruzzone,MarcelloCeppi,Benede
2、ttaConte,4526SamuelMartel,ChristianMaurer,MarcoTagliamento,GiuliaViglietti,711,6LuciaDelMastro,EvandrodeAzambuja,MatteoLambertiniTocite:Poggio F,Bruzzone M,AbstrActPoly(ADP-ribose)polymerase(PARP)isaCeppi M,et al.Single-agentSingle-agentpoly(ADP-ribose)polymerase(PARP)familyofnuclearenzy
3、meswithakeyroleinPARPinhibitorsfortheinhibitors(PARPi)havebeenapprovedasthefirsttargetedtherecognitionandrepairofDNAsingle-treatmentofpatientswiththerapyavailableforpatientswithBRCA-mutatedHER2-strandbreaks.3InthepresenceofPARPBRCA-mutatedHER2-negativenegativemetastaticbreastcancer.Thism
4、eta-analysismetastaticbreastcancer:inhibitors(PARPi),thePARP-dependentasystematicreviewandaimedtobetterevaluateactivity,efficacyandsafetyofDNArepairsystemcannotbeactivatedwithmeta-analysis.ESMOOpensingle-agentPARPiinthispopulation.Asystematicsearchconsequentdevelopmentofdouble-strand2018
5、;3:e000361.doi:10.1136/ofMedline,Embaseandconferenceproceedingsuptoesmoopen-2018-00036131January2018wasconductedtoidentifyrandomisedbreaks.Innormalcells,thesebreakagescancontrolledtrials(RCTs)investigatingsingle-agentPARPiberepairedthroughthehomologousrecom-versusmonochemotherapyinpatien
6、tswithBRCA-binationpathwayswithsubsequentretrievalReceived20March2018mutatedHER2-negativemetastaticbreastcancer.UsingofDNAintegrityandcellsurvival.Conversely,Accepted29March2018therandom-effectmodel,wecalculatedsummaryriskinBRCA-mutatedcells,homologousrecombi-estimates(pooledHRandORwith9
7、5%CI)forprogression-nationisdefectiveandthesedamagescannotfreesurvival(PFS),overallsurvival(OS),objectiveresponsebeefficientlyrepairedresultingincelldeathsrate(ORR),anygradeandgrade3–4adverseevents(AEs),45http://esmoopen.bmj.com/(ie,theconceptofsyntheticlethality).treatme
